Hope S. Rugo
Breast oncologist who led key ADC and CDK4/6 trials and moved from UCSF to City of Hope in 2024.
Medical oncologist who was principal investigator of TROPiCS-02 (sacituzumab govitecan in HR+ breast cancer) and a leader in scalp cooling and toxicity management studies. Joined City of Hope from UCSF in 2024.
| Title | Journal | Year |
|---|---|---|
| Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer | Journal of Clinical Oncology | 2022 |
| Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer | JAMA | 2017 |
Patients whose breast cancer was previously called HER2-negative may now be eligible for an effective HER2-directed drug if their tumour has even low-level HER2 staining, so pathology reports must now distinguish HER2-low (1+ or 2+/ISH-negative) from HER2-zero. This applies to metastatic disease after at least one line of chemotherapy; it does not mean these patients benefit from trastuzumab or other older HER2 drugs.
Sacituzumab govitecan is a standard second-line or later treatment for metastatic triple-negative breast cancer, roughly doubling survival compared with the chemotherapies it was tested against. Patients should expect neutropenia and diarrhoea, which are manageable with growth factor support and loperamide. Trials are now testing it earlier, in first-line combinations with pembrolizumab and after surgery for residual disease.
Pages like this
not linked directly; found by shared links- TrialASCENT
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Sacituzumab govitecan, TROP2, Triple-negative breast cancer (TNBC).
- PersonSara M. Tolaney
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Sacituzumab govitecan, TROP2, Antibody-drug conjugate (ADC).
- TrialASCENT-03
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Sacituzumab govitecan, Triple-negative breast cancer (TNBC).
- IdeaTROP2 PET to choose and sequence TROP2 ADCs
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Sacituzumab govitecan, TROP2, Antibody-drug conjugate (ADC).
- PairingTROP2 PET → TROP2 ADC selection
Shares Sacituzumab govitecan, TROP2, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- PersonSeock-Ah Im
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Palbociclib, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- IdeaDual-payload ADCs in first line to prevent resistance
Shares TROP2, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- IdeaAlpha radioligands after ADC failure
Shares TROP2, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.